scholarly journals Impact of optional multidisciplinary tumor board meeting on the mortality of patients with gastrointestinal cancer: A retrospective observational study

2021 ◽  
Author(s):  
Mohammed Basendowah ◽  
Alaa M. Awlia ◽  
Hanin A. Alamoudi ◽  
Hala M. Ali Kanawi ◽  
Abdulaziz Saleem ◽  
...  
2019 ◽  
Vol 5 (9) ◽  
pp. FSO417
Author(s):  
Paul E George ◽  
Geriga Fahdil ◽  
Israel Luutu ◽  
Alfred Bulamu ◽  
John Sekabira ◽  
...  

Aim: To evaluate the efficacy of a pediatric multidisciplinary tumor board (MTB) in Uganda. Patients & methods: We documented the discussion of cases presented at a pediatric MTB and subsequently, though retrospective chart review, determined the degree to which decision were implemented. Results: 95 patients were discussed. In total, 129 of 226 (57%) distinct management decisions reached during the MTBs were implemented. Of these, 15 resulted in changes in diagnosis and 53 were classified as major changes in management. Decisions on chemotherapy were the most likely to be successfully enacted (51/58), followed by radiotherapy (18/30) and surgery (12/21). Labs/consults were less likely to be implemented. Conclusion: Key improvements, specifically in the documentation and implementation of management decisions, are needed to improve the MTB’s efficacy.


HPB ◽  
2017 ◽  
Vol 19 (2) ◽  
pp. 133-139 ◽  
Author(s):  
David G. Brauer ◽  
Matthew S. Strand ◽  
Dominic E. Sanford ◽  
Vladimir M. Kushnir ◽  
Kian-Huat Lim ◽  
...  

2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.


Sign in / Sign up

Export Citation Format

Share Document